Aliment Pharmacol Ther:维生素D可能在NAFLD发展中发挥作用

2013-09-11 佚名 丁香园

非酒精性脂肪性肝病(NAFLD)是一种高发疾病。新的证据提示维生素D可能在NAFLD发病机制中发挥作用。为了系统性回顾维生素D水平(以血清25–羟维生素D[25(OH)D]判断)与NAFLD之间的关系,来自华盛顿医疗中心M Eliades教授及其团队进行了一项研究,该研究发现NAFLD患者血清25(OH)D浓度下降,提示维生素D可能在NAFLD发展中发挥作用。该研究结果发表在2013年8月的Ali

非酒精性脂肪性肝病(NAFLD)是一种高发疾病。新的证据提示维生素D可能在NAFLD发病机制中发挥作用。为了系统性回顾维生素D水平(以血清25–羟维生素D[25(OH)D]判断)与NAFLD之间的关系,来自华盛顿医疗中心M Eliades教授及其团队进行了一项研究,该研究发现NAFLD患者血清25(OH)D浓度下降,提示维生素D可能在NAFLD发展中发挥作用。该研究结果发表在2013年8月的Alimentary Pharmacology & Therapeutics杂志上。

该研究中,使用PubMed和EMBASE数据库,确定2013年4月22日以前所有评估维生素D与NAFLD关系的研究,没有语言限制。该研究纳入比较NAFLD病例与对照者之间维生素D水平的研究,同时也包括那些比较NAFLD状态夏维生素D缺乏几率的研究。使用反向方差法计算合并标准差和比值比。

该研究结果表明,17项横断面病例对照研究评估维生素D与NAFLD之间关系。分别使用组织活检(4项研究)、超声或CT(10项研究)和肝酶(3项研究)诊断NAFLD.9项研究提供定量荟萃分析的数据。与对照组相比,NAFLD患者25(OH)D水平下降0.36ng/ml,且维生素D缺乏可能性增加1.26倍。

该研究发现,NAFLD患者血清25(OH)D浓度下降,提示维生素D可能在NAFLD发展中发挥作用。这种关系的方向性不能从横断面研究中确定。在未来研究中证明维生素D缺乏在NAFLD发展中的因果作用将有重要的治疗影响。

原文阅读

Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati FL, Potter JJ, Koteish AA, Clark JM, Guallar E, Hernaez R.Meta-analysis: vitamin D and non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2013 Aug;38(3):246-54.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2083873, encodeId=3e2620838e365, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Tue Jul 22 19:20:00 CST 2014, time=2014-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908158, encodeId=60061908158d6, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 23 04:20:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787136, encodeId=f2571e8713696, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 09 12:20:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995886, encodeId=efcd1995886d0, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 23 04:20:00 CST 2013, time=2013-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788148, encodeId=44d01e8814826, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jul 11 15:20:00 CST 2014, time=2014-07-11, status=1, ipAttribution=)]
    2014-07-22 lvygwyt2781
  2. [GetPortalCommentsPageByObjectIdResponse(id=2083873, encodeId=3e2620838e365, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Tue Jul 22 19:20:00 CST 2014, time=2014-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908158, encodeId=60061908158d6, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 23 04:20:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787136, encodeId=f2571e8713696, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 09 12:20:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995886, encodeId=efcd1995886d0, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 23 04:20:00 CST 2013, time=2013-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788148, encodeId=44d01e8814826, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jul 11 15:20:00 CST 2014, time=2014-07-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2083873, encodeId=3e2620838e365, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Tue Jul 22 19:20:00 CST 2014, time=2014-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908158, encodeId=60061908158d6, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 23 04:20:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787136, encodeId=f2571e8713696, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 09 12:20:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995886, encodeId=efcd1995886d0, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 23 04:20:00 CST 2013, time=2013-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788148, encodeId=44d01e8814826, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jul 11 15:20:00 CST 2014, time=2014-07-11, status=1, ipAttribution=)]
    2014-06-09 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=2083873, encodeId=3e2620838e365, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Tue Jul 22 19:20:00 CST 2014, time=2014-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908158, encodeId=60061908158d6, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 23 04:20:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787136, encodeId=f2571e8713696, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 09 12:20:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995886, encodeId=efcd1995886d0, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 23 04:20:00 CST 2013, time=2013-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788148, encodeId=44d01e8814826, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jul 11 15:20:00 CST 2014, time=2014-07-11, status=1, ipAttribution=)]
    2013-09-23 yb6560
  5. [GetPortalCommentsPageByObjectIdResponse(id=2083873, encodeId=3e2620838e365, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Tue Jul 22 19:20:00 CST 2014, time=2014-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908158, encodeId=60061908158d6, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 23 04:20:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787136, encodeId=f2571e8713696, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 09 12:20:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995886, encodeId=efcd1995886d0, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 23 04:20:00 CST 2013, time=2013-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788148, encodeId=44d01e8814826, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jul 11 15:20:00 CST 2014, time=2014-07-11, status=1, ipAttribution=)]

相关资讯

JCEM:老年男性维生素D缺乏可预测全因死亡率

老年人群中维生素D缺乏和虚弱是常见的。为了确定25–羟维生素D[25(OH)D]浓度是否与虚弱和死亡率有关,来自澳大利亚西澳大学的Yuen Yee Elizabeth Wong教授及其团队进行了一项研究,该研究发现维生素D缺乏与虚弱的发生和流行有关,同时可预测全因死亡率。该研究结果在线发表在2013年6月20日的《临床内分泌代谢杂志》(The journal of clinical endocri

Clin Endocrinol:原发性甲旁亢患者补充维生素D可减少PTH分泌

原发性甲旁亢患者循环25-羟维生素D、甲状旁腺激素、磷酸盐和钙之间的关系 尽管NIH临床推荐,许多临床医师在原发性甲状旁腺功能亢进(PHP)伴有高钙血症患者中不愿意使用维生素D替代治疗,因为担心高钙血症进一步恶化。此外,PHP维生素D替代的最佳水平仍不清楚,为此,来自英国伦敦汉姆史密斯医院的Channa N Jayasena教授及其团队进行了一项研究,该研究发现25–羟维生素D水平>60

AP&T:荟萃分析显示维生素D与非酒精性脂肪肝有关

非酒精性脂肪性肝病(NAFLD)呈高发状态。新的证据显示维生素D可能在NAFLD的发病过程中起作用。来自美国的M. Eliades等人近日发表论文,该研究系统回顾维生素D水平、血清25-羟维生素D[25(OH)D]及NAFLD的相关性。研究显示,NAFLD患者有较低的血清25(OH)D浓度,提示维生素D可能在NAFLD的发展中起作用。横断面研究未能对此关系提出明确的指向性。维生素D缺乏在

维生素D浓度低增加患高血压风险

英国伦敦大学学院的一项新研究,其报告警告称,如果人体内的维生素D浓度过低,可能会增加患高血压的风险。英国伦敦大学学院的研究学者分析了35份研究报告,当中包括欧洲、北美共15.5万多人。其研究发现,如果一个人身体含有高浓度的维生素D,出现高血压的机率较低。而且还发现,当身体内的维生素D浓度每增加10%,患高血压的风险就会减少8%,维生素D浓度与患病风险成负相关。因此,可以从已经有研究了解到,人体内维

Clin Endocrinol:产次和肤色是维生素D不足的危险因素

妊娠期间,维生素D不足和缺乏(分别定义为血清25–羟维生素D(25(OH)D)<50nM和<25nM)可能对母亲和孩子都有孩子都有不利的影响。患病率评估和特殊风险亚组的识别可能对预防策略的设计有用。为了研究妊娠早期维生素D缺乏的患病率和危险因素,来自丹麦南方大学H T Christesen教授及其团队进行了一项研究,该研究发现维生素D不足在妊娠早期普遍分布,高加索人中经产妇和没有被晒成棕褐色是

BMC Musculoskelet Disord:维生素D缺乏或与腰背痛有关

腰背痛由于其高发生率,是一种重要的公共健康问题,可导致活动受限,并且许多病例需要手术治疗。女性腰背痛比男性更常见,而且主要在绝经后女性。绝经后女性维生素D缺乏的患病率高,并与骨量丢失、肌肉减少症、椎体骨折和炎症反应相关,而骨量丢失、肌肉减少症、椎体骨折和炎症反应可能与腰背痛有关。为了评估腰背痛与维生素D缺乏之间的关系,以及有和没有维生素D缺乏女性之间卧床不起天数、不能上班天数和日常活动受限的差异,